Hedgehog cell-signalling pathway inhibitor

DRUG CLASS:

Hedgehog cell-signalling pathway inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	vismodegib Sensitive: A2 - Guideline vismodegib Sensitive : A2	vismodegib Sensitive: A2 - Guideline vismodegib Sensitive : A2
SMO mutation	Basal Cell Carcinoma	SMO mutation	Basal Cell Carcinoma	vismodegib Resistant: B - Late Trials vismodegib Resistant : B	vismodegib Resistant: B - Late Trials vismodegib Resistant : B
PTCH1 mutation	Medulloblastoma	PTCH1 mutation	Medulloblastoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH1 mutation	Melanoma	PTCH1 mutation	Melanoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
GLI1 overexpression	Basal Cell Carcinoma	GLI1 overexpression	Basal Cell Carcinoma	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3
PTCH1 mutation	Salivary Gland Cancer	PTCH1 mutation	Salivary Gland Cancer	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
GAS1 underexpression	Basal Cell Carcinoma	GAS1 underexpression	Basal Cell Carcinoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH E947T	Soft Tissue Sarcoma	PTCH E947T	Soft Tissue Sarcoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
SMO P641A	Meningioma	SMO P641A	Meningioma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
SMO W535L	Basal Cell Carcinoma	SMO W535L	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO Q477E	Basal Cell Carcinoma	SMO Q477E	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO D473H	Basal Cell Carcinoma	SMO D473H	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO S533N	Basal Cell Carcinoma	SMO S533N	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO D473G	Basal Cell Carcinoma	SMO D473G	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4
SMTN P641A	Non Small Cell Lung Cancer	SMTN P641A	Non Small Cell Lung Cancer	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4
PTCH1 S616G	Basal Cell Carcinoma	PTCH1 S616G	Basal Cell Carcinoma	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4
ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	GANT1 Sensitive: D – Preclinical GANT1 Sensitive : D	GANT1 Sensitive: D – Preclinical GANT1 Sensitive : D
ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	GANT61 Sensitive: D – Preclinical GANT61 Sensitive : D	GANT61 Sensitive: D – Preclinical GANT61 Sensitive : D
ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical Hedgehog cell-signalling pathway inhibitor Sensitive : D	Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical Hedgehog cell-signalling pathway inhibitor Sensitive : D
ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	cyclopamine Sensitive: D – Preclinical cyclopamine Sensitive : D	cyclopamine Sensitive: D – Preclinical cyclopamine Sensitive : D
ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma	sonidegib Sensitive: D – Preclinical sonidegib Sensitive : D	sonidegib Sensitive: D – Preclinical sonidegib Sensitive : D
PTCH1 deletion	Medulloblastoma	PTCH1 deletion	Medulloblastoma	IPI 926 oral Sensitive: D – Preclinical IPI 926 oral Sensitive : D	IPI 926 oral Sensitive: D – Preclinical IPI 926 oral Sensitive : D
SUFU deletion	Medulloblastoma	SUFU deletion	Medulloblastoma	sonidegib Resistant: D – Preclinical sonidegib Resistant : D	sonidegib Resistant: D – Preclinical sonidegib Resistant : D
MYCN amplification	Medulloblastoma	MYCN amplification	Medulloblastoma	sonidegib Resistant: D – Preclinical sonidegib Resistant : D	sonidegib Resistant: D – Preclinical sonidegib Resistant : D
PTCH1 mutation	Medulloblastoma	PTCH1 mutation	Medulloblastoma	sonidegib Sensitive: D – Preclinical sonidegib Sensitive : D	sonidegib Sensitive: D – Preclinical sonidegib Sensitive : D
SMO D473H	Medulloblastoma	SMO D473H	Medulloblastoma	vismodegib Resistant: D – Preclinical vismodegib Resistant : D	vismodegib Resistant: D – Preclinical vismodegib Resistant : D
SMO D473H	Medulloblastoma	SMO D473H	Medulloblastoma	IPI 926 oral Sensitive: D – Preclinical IPI 926 oral Sensitive : D	IPI 926 oral Sensitive: D – Preclinical IPI 926 oral Sensitive : D
GLI1 expression	Pancreatic Ductal Adenocarcinoma	GLI1 expression	Pancreatic Ductal Adenocarcinoma	sonidegib Sensitive: D – Preclinical sonidegib Sensitive : D	sonidegib Sensitive: D – Preclinical sonidegib Sensitive : D

Hedgehog cell-signalling pathway inhibitor

Hedgehog cell-signalling pathway inhibitor

Associations(34)

Associations
(34)